ELEloxx Pharmaceuticals, Inc. ELOX NASDAQ · Healthcare · United States
$10.69 +0.38% +$0.04
- Market cap
- $36.6M
- Enterprise value
- $32.8M
- P/E
- -
- Forward P/E
- -
- PEG
- -
- P/S
- -
- P/FCF
- -
- EV/EBITDA
- -
- ROIC
- 59.0%
- Gross margin
- -
- Net margin
- -
- Dividend yield
- -
- Payout ratio
- -
- Net debt/EBITDA
- -
- Beta
- -9.95
- Free float
- 9.0%
About the company
Eloxx Pharmaceuticals, Inc. (ELOX) is a biotechnology company specializing in the development of therapeutic therapies for genetic diseases and rare conditions. The company focuses on developing drug products that can correct genetic mutations and provide treatment for patients suffering from genetic disorders. Eloxx Pharmaceuticals targets the treatment of rare diseases such as cystic fibrosis, Duchenne muscular dystrophy, and other genetic disorders. With the growing awareness of the need for genetic disease treatment, Eloxx Pharmaceuticals, Inc. has the potential for sustained growth. Eloxx Pharmaceuticals, Inc. (ELOX) shares might be an interesting choice for investors seeking involvement in the biotechnology and therapeutic therapies for genetic diseases.
Sector
Healthcare
Industry
Biotechnology
CEO
Sumit Aggarwal
Employees
10
Headquarters
Watertown
Valuation
Is today's price reasonable?
Growth and estimates
Is it growing, and what comes next?
Profitability and quality
How much of the revenue is left, and how well does the company use its capital?
- What speaks for it: It earns 59 USD a year on every 100 USD of invested capital.
Financial health
Can it carry its debt?
- What speaks for it: It holds more cash than debt: $56.3M against $11.8M.
- What to watch: It passes only 3 of the 9 points of the Piotroski financial health test.
- What to watch: For every 100 USD of bills due within a year it has 31 USD of short-term assets.
Capital and dividends
What does the company do with the money it earns?
Analysts
What do the professionals think, and is it changing?
Owners and insiders
Who holds the stock, and what is management doing?
Segments
Which part of the company is growing?
Peer comparison
How does it compare with similar companies?
Price and risk
How does the stock behave?
Statements
Every number